Stock analysts at StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN – Get Free Report) in a report issued on Thursday. The firm set a “hold” rating on the specialty pharmaceutical ...

The TRAVERSE trial, a large-scale clinical study with over 5,000 patients, published in 2023, concluded that TRT does not increase the risk of adverse cardiovascular outcomes in men with hypogonadism.

Marius Pharmaceuticals, a pharmaceutical company dedicated to developing innovative therapies for testosterone deficiency, has partnered with Duke University School of Medicine to explore the ...

has implemented significant labeling changes for KYZATREX® (testosterone undecanoate) CIII capsules. This decision follows the conclusion of the TRAVERSE trial and comprehensive blood pressure ...

Grünenthal is paying up to €500 million ($501 million) for rights to Nebido (testosterone undecanoate), which is sold in around 80 countries worldwide for testosterone deficiency and made sales ...

For more information, please visit www.mariuspharma.com. About KYZATREX® (testosterone undecanoate) KYZATREX is a proprietary softgel oral formulation absorbed primarily via the lymphatic system ...

Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. Receive News & Ratings for Lipocine Daily - Enter your email address below ...

New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.